Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
The veterinary vaccine producer raised a modest $6.9 million in its New York listing by selling just 3% of its shares, as it diversifies into the household pets market Key…
PODCAST: China-built Battery Plant Hits the Skids in U.S., and Pet Site Boqii Bows from NYSE
By Doug Young & Rene Vanguestaine Ford has put the brakes on a battery plant being built for it in the U.S. by China’s CATL. Is this the end of…
Boqii Delists, Ends Three-Year ‘Ruff’ Ride on NYSE
Not enough dog years left for the pet-care company, whose falling market value put it in danger of being forcibly delisted after its revenue contracted in its latest fiscal year…
New Ruipeng Trots Out ‘Pet Project’ IPO
China’s largest provider of pet products and services could raise as much as $400 million from its plan to list in New YorkKey Takeaways:New Ruipeng has filed for a New…
Boqii Barks With Latest Earnings Report, But Investors Beg for Profits
Online pet community operator’s margins improved sharply in the three months to June, bringing it closer to elusive profits Key Takeaways: Boqii’s revenue dropped slightly in the three months to…
Me-ow! Pet Community Operator Boqii Faces Delisting Due to Shriveling Valuation
Company says it could be forced off the New York Stock Exchange after its market cap fell below $50 million for 30 days Key Takeaways: Boqii could face delisting from…
Boqii Cuddles Up to Premium U.S. Pet Food Maker
Online pet community operator signals intent to make more strategic investments as it buys undisclosed stake in Better Choice Key Points: Boqii’s investment in U.S. premium pet food maker Better…
Recent Articles
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Aging population, declining birthrate fluff up China’s ‘Furry Economy’
-
Dogness limps ahead as investors chase its stock
DOGZ.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Plenty of room for growth in China’s hair transplant market
